• Disease Overview
  • Synonyms
  • Signs & Symptoms
  • Causes
  • Affected Populations
  • Disorders with Similar Symptoms
  • Diagnosis
  • Standard Therapies
  • Clinical Trials and Studies
  • References
  • Programs & Resources
  • Complete Report

Familial Calcium Pyrophosphate Deposition Disease


Last updated: 10/31/2023
Years published: 1986, 1988, 1989, 1995, 2003, 2018, 2023


NORD gratefully acknowledges Amanda Wong, NORD Editorial Intern from the Keck Graduate Institute and Ann K. Rosenthal, MD, FACP, Will and Cava Ross Professor of Medicine and Chief of Rheumatology, Medical College of Wisconsin, for assistance in the preparation of this report.

Disease Overview


Chondrocalcinosis 1 and 2 (CCAL1 and CCAL2) are genetic forms of calcium pyrophosphate deposition disease (CPPD), a metabolic disorder characterized by deposits of calcium pyrophosphate crystals (CPP) in joint cartilage and eventual damage to affected joints. The symptoms of CCAL1 and CCAL2 include swelling, stiffness, pain and loss of function of the affected joints. The knee is the most affected area. CCAL1 and CCAL2 are autosomal dominant genetic disorders that are usually diagnosed in early adulthood.


The non-genetic forms of CPDD are much more common, and typically cause arthritis in patients over the age of 60.

  • Next section >
  • < Previous section
  • Next section >


  • chondrocalcinosis 1 (CCAL1)
  • chondrocalcinosis 2 (CCAL2)
  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Signs & Symptoms

The symptoms of CCAL1 and CCAL2 usually begin as acute, recurring attacks of pain, swelling, warmth and redness in one or more joints. Other affected people have swelling, stiffness, and pain with little or no inflammation in the joints. A knee, wrist, hip, or shoulder is most frequently affected, although any joint of the body may be involved. Acute episodes can last for days to weeks, and symptoms may go away without treatment. CPP deposits may accumulate around the bones of the spine (vertebrae) and cause back or neck pain and/or loss of mobility. Many patients with CPPD develop chronic arthritis which can resemble osteoarthritis or rheumatoid arthritis.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


CCAL2 is caused by changes (variants or mutations) in the ANKH gene that lead to an increased amount of the ANKH protein produced.

The protein produced by the ANKH gene seems to be involved in cellular transport of ATP. ATP is an important energy-containing compound. In cartilage, when it is transported outside the cell, it is metabolized by enzymes into inorganic pyrophosphate (PPi). Variants in ANKH have been shown to have a significant effect on the regulation of extracellular ATP and PPi levels (outside chondrocytes). When ANKH activity is increased, levels of PPi accumulate in cartilage, complex with calcium and form calcium pyrophosphate (CPP) crystals.

CCAL1 is caused by variants in the TNFSRF11B gene that lead to a reduced amount of the osteoprotegerin protein produced.

Osteoprotegerin is made by both bone and cartilage and regulates the activity of cells known as osteoclasts which cause bone loss. When osteoprotegerin is not fully functional, osteoclasts increase in number and activity. Exactly how and why this causes CPPD is not yet known.

In most cases, CCAL1 and CCAL2 follow autosomal dominant inheritance. Dominant genetic disorders occur when only a single copy of a mutated gene is necessary to cause the disease. The mutated gene can be inherited from either parent or can be the result of a changed gene in the affected individual. The risk of passing the mutated gene from an affected parent to a child is 50% for each pregnancy. The risk is the same for males and females.

In some individuals, the disorder is due to a spontaneous (de novo) genetic mutation that occurs in the egg or sperm cell. In such situations, the disorder is not inherited from the parents.

The symptoms of CCAL1 and CCAL2 are thought to be more severe in people who carry two gene variants for the disorder (homozygotes), one from each parent. People who have only one abnormal gene (heterozygotes) are thought to experience less severe symptoms.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Affected populations

CCAL1 and CCAL2 are rare disorders. Eight families have been described in the medical literature with CCAL2. Four families with TNFSRF11B gene variants associated with CCAL1 have been identified. There is no known ethnic or sex predilection.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


Few or no symptoms may be apparent in the first several decades of life. X-rays of joints, especially the knees and wrists, may detect calcifications before symptoms occur. The diagnosis of CCAL1 and CCAL2 is based on a clinical evaluation that includes a thorough patient history and specialized laboratory tests. In one test, fluid is removed from an affected joint (synovial fluid). The presence of calcium pyrophosphate crystals in this fluid confirms the diagnosis of articular chondrocalcinosis. Radiographic (x-ray) studies typically demonstrate calcium pyrophosphate deposits in the cartilage in joints (articular).

Joint ultrasonography is well tolerated by patients and is another method of observing calcified deposits in soft tissues.

Molecular genetic testing for mutations in the ANKH gene is available to confirm the diagnosis of CCAL2.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Standard Therapies

Treatment for CCAL1 and CCAL2 is symptomatic. There is no way to prevent the formation of calcium pyrophosphate crystals or to satisfactorily remove existing crystals from the joints.

Acute attacks of CCAL1 and CCAL2 are treated in several ways. Excess fluid may be drained from the affected joint using a needle and syringe. If only one joint is involved, a corticosteroid drug may be injected directly into the affected joint (intra-articular). For individuals with frequent, recurring acute attacks, colchicine or oral corticosteroids such as prednisone may be effective. These medications are also used to treat gout. Other drugs that are frequently used include nonsteroidal anti-inflammatory drugs (e.g., ibuprofen and naproxen sodium) which are commonly prescribed for many types of arthritic conditions.

When corticosteroids, nonsteroidal anti-inflammatory drugs and colchicine are ineffective, contraindicated or not well-tolerated, drugs that inhibit the cytokine interleukin 1 alpha might be helpful. There is some evidence that methotrexate and hydroxychloroquine may also be useful, but the effectiveness of these drugs is not well studied.

During an acute attack of arthritis, the affected joint may require rest. Splints, canes and other devices that protect and support the joint may be prescribed and may require special fitting. Once the episode subsides, rest should be balanced with appropriate exercise that is carefully monitored by a physician or physical therapist.

In some people with CCAL1 or CCAL2, surgery may be necessary to repair a joint that is badly damaged. Surgery may be an effective means for reducing pain and enhancing mobility in some people.

Asymptomatic CCAL1 and CCAL2 do not require treatment.

Genetic counseling may be helpful for affected individuals and their families.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Clinical Trials and Studies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov

Some current clinical trials also are posted on the following page on the NORD website:

For information about clinical trials sponsored by private sources, contact:

For information about clinical trials conducted in Europe, contact:

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


O’Duffy, JD. Familial Articular Chondrocalcinosis. In: The NORD Guide to Rare Disorders, Philadelphia: Lippincott, Williams and Wilkins, 2003:169-170.

Rosenthal AK and Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575-2584. DOI: 10.1056/NEJMra1511117

Rosales-Alexander JL, Balsalobre Aznar J, Magro-Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatology : Research and Reviews. 2014;6:39-47. doi:10.2147/OARRR.S39039

MacMullan P, McCarthy G. Treatment and management of pseudogout: insights for the clinician. Therapeutic Advances in Musculoskeletal Disease. 2012;4(2):121-131. doi:10.1177/1759720X11432559

Filippou G, Frediani B, Gallo A, et al. A “new” technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high‐frequency ultrasonography. Annals of the Rheumatic Diseases. 2007;66(8):1126-1128. doi:10.1136/ard.2007.069344

Zaka R, Williams CJ. Genetics of chondrocalcinosis. Osteoarthritis and cartilage. Osteoarthritis Cartilage. 2005 Sep;13(9):745-50.
Zarins B, McInerney VK. Calcium pyrophosphate and pseudogout. Arthroscopy; 1985;1(1):8-16.

Chondrocalcinosis 2. Genetic and Rare Diseases Information Center. Last updated: 1/12/2018. https://rarediseases.info.nih.gov/diseases/1292/chondrocalcinosis-2 Accessed Oct 30, 2023.

Patient education: Calcium pyrophosphate crystal deposition (CPPD) disease (Beyond the Basics). UptoDate. Oct 13, 2021. https://www.uptodate.com/contents/calcium-pyrophosphate-crystal-deposition-cppd-disease-beyond-the-basics Accessed Oct 30, 2023.

Familial calcium pyrophosphate deposition. Orphanet. Last update: July 2020. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=1416 Accessed Oct 31, 2023.

McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University; Chondrocalcinosis 2. Entry no. 118600; Last Update: 12/07/2022. Available at: https://www.omim.org/entry/118600 Accessed Oct 30, 2023.

McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University; Chondrocalcinosis 1. Entry no. 600668; Last Update: 09/25/2020. Available at: https://www.omim.org/entry/600668 Accessed Oct 30, 2023.

  • < Previous section
  • Next section >

Programs & Resources

RareCare® Assistance Programs

NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.

Additional Assistance Programs

MedicAlert Assistance Program

NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.

Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/

Rare Disease Educational Support Program

Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.

Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/

Rare Caregiver Respite Program

This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.

Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/

Patient Organizations

National Organization for Rare Disorders